Clene (NASDAQ:CLNN) Major Shareholder Sells $64,071.30 in Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 12,563 shares of the business’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $5.10, for a total transaction of $64,071.30. Following the sale, the insider owned 650,298 shares in the company, valued at approximately $3,316,519.80. This trade represents a 1.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The stock was sold at an average price of $5.12, for a total transaction of $100,459.52.
• On Tuesday, January 13th, Chidozie Ugwumba sold 26,105 shares of Clene stock. The shares were sold at an average price of $4.89, for a total transaction of $127,653.45.
• On Monday, January 12th, Chidozie Ugwumba sold 32,705 shares of Clene stock. The stock was sold at an average price of $5.50, for a total transaction of $179,877.50.
• On Friday, January 9th, Chidozie Ugwumba sold 9,075 shares of Clene stock. The shares were sold at an average price of $6.27, for a total transaction of $56,900.25.
• On Thursday, January 8th, Chidozie Ugwumba sold 3,195 shares of Clene stock. The shares were sold at an average price of $6.09, for a total transaction of $19,457.55.
• On Wednesday, January 7th, Chidozie Ugwumba sold 3,938 shares of Clene stock. The stock was sold at an average price of $6.29, for a total value of $24,770.02.
• On Tuesday, January 6th, Chidozie Ugwumba sold 3,111 shares of Clene stock. The shares were sold at an average price of $6.04, for a total value of $18,790.44.
• On Monday, January 5th, Chidozie Ugwumba sold 5,869 shares of Clene stock. The shares were sold at an average price of $5.87, for a total value of $34,451.03.
• On Friday, January 2nd, Chidozie Ugwumba sold 4,015 shares of Clene stock. The stock was sold at an average price of $5.73, for a total value of $23,005.95.
• On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The shares were sold at an average price of $5.81, for a total value of $76,081.95.

Clene Stock Performance

Shares of CLNN traded up $0.10 during trading hours on Friday, hitting $5.21. The company had a trading volume of 31,933 shares, compared to its average volume of 130,336. The stock has a market capitalization of $56.57 million, a price-to-earnings ratio of -1.54 and a beta of 0.87. The firm has a fifty day moving average price of $7.23 and a 200-day moving average price of $6.44. Clene Inc. has a 52-week low of $2.28 and a 52-week high of $13.50.

Clene (NASDAQ:CLNN) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. Research analysts anticipate that Clene Inc. will post -5.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Clene

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Lunt Capital Management Inc. increased its stake in Clene by 2.5% in the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock worth $315,000 after acquiring an additional 1,250 shares during the last quarter. Jones Financial Companies Lllp bought a new stake in Clene in the third quarter worth $29,000. Jane Street Group LLC purchased a new stake in Clene during the second quarter valued at $47,000. Finally, Scoggin Management LP lifted its position in Clene by 42.8% during the second quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after purchasing an additional 42,750 shares during the last quarter. 23.28% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on CLNN shares. UBS Group reiterated a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Benchmark reiterated a “buy” rating on shares of Clene in a report on Thursday, December 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a report on Friday, January 9th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Clene in a report on Friday, January 9th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Clene has an average rating of “Moderate Buy” and an average price target of $32.60.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).